摘 要 目的: 评价DCIK细胞过继免疫治疗急性髓细胞性白血病（acute myeloid leukemia，AML）的临床疗效。方法：选取苏州大学附属第一医院2006年1月至2007年12月所收治的10例确诊AML患者，经常规化疗后处于完全缓解中，经院伦理委员会批准和患者知情同意，用血细胞分析仪分离外周血中单个核细胞(peripheral blood mononuclear cells，PBMC)，在体外诱导培养成DCIK细胞；以流式细胞术检测DCIK细胞的表型，以MTT法检测DCIK细胞对人红白血病细胞K562的杀伤活性，确认质量合格后回输给患者进行抗肿瘤免疫治疗；治疗后评价其近期临床疗效、免疫学活性及不良反应等。结果：体外成功诱导培养DCIK细胞，其对白血病细胞株K562的杀伤率为(58.3±3.3)%；DCIK细胞群中，CD3+CD56+ 占(38.4±9.42)%。10例患者经治疗后，7例持续完全缓解（continuous complete remission，CCR），占70%；患者回输DCIK后外周血中的CD4+ 、CD8+ 、CD56+ 的比例均有明显提高(P<0.05或P<0.01)；无一患者出现严重不良反应。结论：DCIK能诱导机体产生特异性的免疫反应，对急性髓细胞性白血病的治疗有较好的临床疗效。

Abstract Objective: To investigate the clinical anticancer efficacy of cocultured dendritic cells with cytokineinduced killer cells (DCIK) in treating patients with acute myeloid leukemia (AML). Methods: Totally 10 patients, who were diagnosed as AML and completely remitted after chemical therapy in the First Affiliated Hospital of Suzhou University from Jan. 2006 to Dec. 2007, were included in this study. Peripheral blood mononuclear cells (PBMC) isolated from these patients were treated with standard protocol and were induced to DCIK cells, which were identified by flow cytometry. MTT assay was used to evaluate the cytotoxic effect of DCIK cells against K562 cells. The qualified DCIK cells were administered to the patients and the clinical anticancer efficacy, immunological activity and side effects were evaluated. Results: The cultured DCIK cells inhibited the K562 cells by (58.3±3.3) %. In DCIK cells administered to patients, the proportion of CD3+CD56+ cells was (38.4±9.42)%. Among the 10 patients received DCIK therapy, 7 had continuous complete remission (70%), 2 had recurrence and 1 had tumorbearing survival. The ratios of CD4+, CD8+, and CD56+ cells in patients′ peripheral blood obviously increased after DCIK infusion. No patients had serious adverse event. Conclusion: DCIK can induce specific immunoreaction in the immune system and has satisfactory clinical anticancer efficacy in treatment of AML.

上海市科委重大科技攻关计划资助项目（No.05DZ19311）